Pliant Therapeutics

Pliant Therapeutics

Biotechnology Research

South San Francisco, California 11,607 followers

We are transforming the lives of patients by developing best-in-class treatments for fibrotic diseases.

Über uns

Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. At Pliant, we share a commitment and a clear passion to drive innovative science towards addressing areas of unmet medical need. Together we believe we have the power to make a difference in the lives of patients and those impacted by fibrotic diseases. We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases. Pliant recognizes the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. Pliant is an equal opportunity employer and does not discriminate against any individual or potential candidate based on race, color, religion, sex, national origin, sexual preference or any other legally protected category. Pliant is located in South San Francisco, California, the birthplace of biotechnology. Proud to be a San Francisco Business Times Best Place to Work in 2023. Learn more about how we are breaking ground in the treatment of fibrotic diseases at www.PliantRx.com.

Website
http://www.pliantrx.com
Industrie
Biotechnology Research
Größe des Unternehmens
51-200 Mitarbeiter
Hauptsitz
South San Francisco, California
Typ
Öffentliches Unternehmen
Gegründet
2015
Spezialitäten
fibrosis, integrins, muscle biology, oncology, Duchenne muscular dystrophy, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, muscular dystrophy, Metabolic dysfunction-associated steatohepatitis, and MASH

Standorte

Employees at Pliant Therapeutics

Aktualisierungen

Ähnliche Seiten

Jobs durchsuchen

Finanzierung

Pliant Therapeutics 5 total rounds

Letzte Runde

Eigenkapital nach dem IPO

US$ 287.5M

Siehe mehr Informationen auf crunchbase